U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Prostate Carcinoma

MedGen UID:
1710824
•Concept ID:
C5238404
•
Neoplastic Process

Definition

Prostate carcinoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma.
Chang SS, Benson MC, Campbell SC, Crook J, Dreicer R, Evans CP, Hall MC, Higano C, Kelly WK, Sartor O, Smith JA Jr; Society of Urologic Oncology, Shaumberg, Illinois
Cancer 2005 Jan 1;103(1):11-21. doi: 10.1002/cncr.20726. PMID: 15558815
Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prostate carcinoma.
Walther PJ
World J Urol 2000 Jun;18(3):216-21. doi: 10.1007/s003450000126. PMID: 10926086
Treatment of hormone-refractory prostate carcinoma.
Fournier G
Eur Urol 1996;30 Suppl 1:32-7. doi: 10.1159/000474243. PMID: 8977988

Recent clinical studies

Etiology

Radiotherapy and concurrent metronomic chemotherapy in hormone-refractory prostate carcinoma: a Phase I study.
Morganti AG, Massaccesi M, Caravatta L, Macchia G, Picardi V, Deodato F, Ippolito E, Mignogna S, Ferro M, Cilla S, Mattiucci GC, Valentini V
Anticancer Res 2013 Oct;33(10):4585-9. PMID: 24123034
Targeting the endothelin axis in prostate carcinoma.
Pinto A, Merino M, Zamora P, Redondo A, Castelo B, Espinosa E
Tumour Biol 2012 Apr;33(2):421-6. Epub 2011 Dec 29 doi: 10.1007/s13277-011-0299-6. PMID: 22203496
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.
Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R
Cancer 2003 Oct 15;98(8):1643-8. doi: 10.1002/cncr.11713. PMID: 14534880
Hormone therapy for patients with prostate carcinoma.
Klotz L
Cancer 2000 Jun 15;88(12 Suppl):3009-14. doi: 10.1002/1097-0142(20000615)88:12+<3009::aid-cncr17>3.3.co;2-5. PMID: 10898345
A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma.
Chang AY, Bennett JM, Pandya KJ, Asbury R, McCune C
Am J Clin Oncol 1989 Aug;12(4):358-60. doi: 10.1097/00000421-198908000-00017. PMID: 2474242

Diagnosis

Study and detection of potential markers for predicting metastasis into lymph nodes in prostate cancer.
Papasotiriou I, Apostolou P, Ntanovasilis DA, Parsonidis P, Osmonov D, Jünemann KP
Biomark Med 2020 Oct;14(14):1317-1327. Epub 2020 Aug 17 doi: 10.2217/bmm-2020-0372. PMID: 32799659
Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.
Zuco V, Supino R, De Cesare M, Carenini N, Perego P, Gatti L, Pratesi G, Pisano C, Martinelli R, Bucci F, Zanier R, Carminati P, Zunino F
Biochem Pharmacol 2003 Apr 15;65(8):1281-94. doi: 10.1016/s0006-2952(03)00079-0. PMID: 12694869
Hormone therapy for patients with prostate carcinoma.
Klotz L
Cancer 2000 Jun 15;88(12 Suppl):3009-14. doi: 10.1002/1097-0142(20000615)88:12+<3009::aid-cncr17>3.3.co;2-5. PMID: 10898345
Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma.
Fujikawa K, Matsui Y, Fukuzawa S, Takeuchi H
Eur Urol 2000 Feb;37(2):218-22. doi: 10.1159/000020121. PMID: 10705202
Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells.
Siegsmund MJ, Stendler A, Kreukler C, Köhrmann KU, Alken P
Eur Urol 1997;31(3):365-70. doi: 10.1159/000474485. PMID: 9129933

Therapy

Targeting the endothelin axis in prostate carcinoma.
Pinto A, Merino M, Zamora P, Redondo A, Castelo B, Espinosa E
Tumour Biol 2012 Apr;33(2):421-6. Epub 2011 Dec 29 doi: 10.1007/s13277-011-0299-6. PMID: 22203496
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.
Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R
Cancer 2003 Oct 15;98(8):1643-8. doi: 10.1002/cncr.11713. PMID: 14534880
Hormone therapy for patients with prostate carcinoma.
Klotz L
Cancer 2000 Jun 15;88(12 Suppl):3009-14. doi: 10.1002/1097-0142(20000615)88:12+<3009::aid-cncr17>3.3.co;2-5. PMID: 10898345
Estramustine-based chemotherapy.
Hudes G
Semin Urol Oncol 1997 Feb;15(1):13-9. PMID: 9050135
Treatment of hormone-refractory prostate carcinoma.
Fournier G
Eur Urol 1996;30 Suppl 1:32-7. doi: 10.1159/000474243. PMID: 8977988

Prognosis

Study and detection of potential markers for predicting metastasis into lymph nodes in prostate cancer.
Papasotiriou I, Apostolou P, Ntanovasilis DA, Parsonidis P, Osmonov D, Jünemann KP
Biomark Med 2020 Oct;14(14):1317-1327. Epub 2020 Aug 17 doi: 10.2217/bmm-2020-0372. PMID: 32799659
Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R, Srirangam SJ, Pearson E, Brown SC, O'Reilly P, Collins GN
Urol Int 2005;75(3):217-21. doi: 10.1159/000087797. PMID: 16215308
Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.
Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF
Cancer 2002 Aug 1;95(3):506-12. doi: 10.1002/cncr.10709. PMID: 12209742
Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma.
Trivedi C, Redman B, Flaherty LE, Kucuk O, Du W, Heilbrun LK, Hussain M
Cancer 2000 Jul 15;89(2):431-6. doi: 10.1002/1097-0142(20000715)89:2<431::aid-cncr31>3.0.co;2-b. PMID: 10918176
Estramustine-based chemotherapy.
Hudes G
Semin Urol Oncol 1997 Feb;15(1):13-9. PMID: 9050135

Clinical prediction guides

Study and detection of potential markers for predicting metastasis into lymph nodes in prostate cancer.
Papasotiriou I, Apostolou P, Ntanovasilis DA, Parsonidis P, Osmonov D, Jünemann KP
Biomark Med 2020 Oct;14(14):1317-1327. Epub 2020 Aug 17 doi: 10.2217/bmm-2020-0372. PMID: 32799659
Anti-tumor activity of non-nucleosidic reverse transcriptase inhibitors.
Landriscina M, Spadafora C, Cignarelli M, Barone C
Curr Pharm Des 2007;13(7):737-47. doi: 10.2174/138161207780249191. PMID: 17346188
Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy.
Oh WK
Cancer 2000 Jun 15;88(12 Suppl):3015-21. doi: 10.1002/1097-0142(20000615)88:12+<3015::aid-cncr18>3.0.co;2-m. PMID: 10898346
Estramustine-based chemotherapy.
Hudes G
Semin Urol Oncol 1997 Feb;15(1):13-9. PMID: 9050135
A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma.
Chang AY, Bennett JM, Pandya KJ, Asbury R, McCune C
Am J Clin Oncol 1989 Aug;12(4):358-60. doi: 10.1097/00000421-198908000-00017. PMID: 2474242

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...